Literature DB >> 1318708

Induction of protective immunity and neutralizing antibodies to pseudorabies virus by immunization of anti-idiotypic antibodies.

T Tsuda1, T Onodera, T Sugimura, Y Murakami.   

Abstract

Xenogenic anti-idiotypic antibodies (anti-Id) were prepared in rabbits against three murine neutralizing monoclonal antibodies (MAbs) directed to pseudorabies virus glycoproteins. These anti-Id were highly specific to idiotopes on the corresponding MAb molecules. Because the binding of MAb to the corresponding anti-Id was inhibited by the addition of viral envelope protein, these anti-Id seemed to contain a subpopulation of antibodies against the antigen-combining site (paratope) or the region related to the paratope of the MAb molecules. One of the anti-Id to a MAb directed against glycoprotein gp50 induced neutralizing antibodies to PrV. Mice immunized with the anti-Id were protected from lethal infection of PrV.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1318708     DOI: 10.1007/bf01309810

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  21 in total

1.  THE APPEARANCE OF COMPLEMENT-REQUIRING NEUTRALIZING ANTIBODIES BY IMMUNIZATION AND INFECTION WITH HERPES SIMPLEX VIRUS.

Authors:  K YOSHINO; S TANIGUCHI
Journal:  Virology       Date:  1964-02       Impact factor: 3.616

2.  Evaluation of pseudorabies virus glycoprotein gp50 as a vaccine for Aujeszky's disease in mice and swine: expression by vaccinia virus and Chinese hamster ovary cells.

Authors:  C C Marchioli; R J Yancey; E A Petrovskis; J G Timmins; L E Post
Journal:  J Virol       Date:  1987-12       Impact factor: 5.103

3.  Mapping and characterization of neutralizing epitopes of glycoproteins gIII and gp50 of the Indiana-Funkhauser strain of pseudorabies virus.

Authors:  N E Coe; W L Mengeling
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

4.  Suppression of delayed type hypersensitivity to herpes simplex virus type 1 following immunization with anti-idiotypic antibody: an example of split tolerance.

Authors:  J L Lathey; S Martin; B T Rouse
Journal:  J Gen Virol       Date:  1987-04       Impact factor: 3.891

5.  In vivo and in vitro genetic recombination between conventional and gene-deleted vaccine strains of pseudorabies virus.

Authors:  L M Henderson; J B Katz; G A Erickson; J E Mayfield
Journal:  Am J Vet Res       Date:  1990-10       Impact factor: 1.156

6.  Induction of antibodies to pseudorabies virus by immunization with antiidiotypic antibodies.

Authors:  M F Gurish; T Ben-Porat; A Nisonoff
Journal:  Ann Inst Pasteur Immunol       Date:  1988 Nov-Dec

7.  Anti-idiotypic antibodies induce neutralizing antibodies to bovine herpesvirus 1.

Authors:  S Srikumaran; D V Onisk; M V Borca; C Nataraj; T J Zamb
Journal:  Immunology       Date:  1990-07       Impact factor: 7.397

8.  Identification of the pseudorabies virus glycoprotein gp50 as a major target of neutralizing antibodies.

Authors:  M Eloit; D Fargeaud; R L'Haridon; B Toma
Journal:  Arch Virol       Date:  1988       Impact factor: 2.574

9.  Protection of mice from lethal infection with Aujeszky's disease virus by immunization with purified gVI.

Authors:  H Ishii; Y Kobayashi; M Kuroki; Y Kodama
Journal:  J Gen Virol       Date:  1988-06       Impact factor: 3.891

10.  Production of cell-mediated immune response to herpes simplex virus by immunization with anti-idiotypic heteroantisera.

Authors:  P G Gell; P A Moss
Journal:  J Gen Virol       Date:  1985-08       Impact factor: 3.891

View more
  2 in total

Review 1.  Molecular biology of pseudorabies virus: impact on neurovirology and veterinary medicine.

Authors:  Lisa E Pomeranz; Ashley E Reynolds; Christoph J Hengartner
Journal:  Microbiol Mol Biol Rev       Date:  2005-09       Impact factor: 11.056

Review 2.  Moloney leukemia virus-induced cell surface antigen mimicry by monoclonal antibodies.

Authors:  J G Baskin; T J Powell; R V Srinivas; M Elliott; E W Lamon
Journal:  Immunol Res       Date:  1995       Impact factor: 2.829

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.